Market Price

303.80 

10.90 -0.5%

as of May 19 '22

52 Week Range:

283.40 553.80


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 4.03
3.96
4.39
5.29
6.31
7.28
8.64
10.50
11.92
14.62
18.10
growth rate -1.7% 10.9% 20.5% 19.3% 15.4% 18.7% 21.5% 13.5% 22.7% 23.8%
Earnings BIT 104.66
121.47
196.99
241.12
250.79
286.88
347.90
503.14
882.78
growth rate 16.1% 62.2% 22.4% 4.0% 14.4% 21.3% 44.6% 75.5%
Avg.PE 40.00
41.14
42.03
42.03
42.03
112.34
growth rate 2.9% 2.2% 0.0% 0.0% 167.3%
ROA 6.25
7.49
7.96
8.15
11.96
13.59
12.39
13.99
13.83
14.64
11.81
growth rate 19.8% 6.3% 2.4% 46.8% 13.6% -8.8% 12.9% -1.1% 5.9% -19.3%
ROE 11.34
13.74
14.56
14.34
20.10
21.96
19.77
21.80
21.37
27.33
26.60
growth rate 21.2% 6.0% -1.5% 40.2% 9.3% -10.0% 10.3% -2.0% 27.9% -2.7%
ROIC 9.13
10.74
11.43
11.93
17.16
19.36
17.35
19.00
19.17
21.70
19.45
growth rate 17.6% 6.4% 4.4% 43.8% 12.8% -10.4% 9.5% 0.9% 13.2% -10.4%
Cur. Ratio 1.31
0.98
1.67
1.20
1.29
1.52
1.40
1.45
1.48
1.54
1.40
growth rate -25.2% 70.4% -28.1% 7.5% 17.8% -7.9% 3.6% 2.1% 4.1% -9.1%
Quick Ratio 0.83
0.52
0.97
0.65
0.67
0.80
0.73
0.69
0.62
0.58
0.57
growth rate -37.4% 86.5% -33.0% 3.1% 19.4% -8.8% -5.5% -10.1% -6.5% -1.7%
Leverage 1.83
1.84
1.82
1.70
1.66
1.58
1.61
1.52
1.57
2.10
2.39
growth rate 0.6% -1.1% -6.6% -2.4% -4.8% 1.9% -5.6% 3.3% 33.8% 13.8%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 115.27
133.68
154.57
206.64
237.62
235.77
242.61
263.96
371.72
growth rate 16.0% 15.6% 33.7% 15.0% -0.8% 2.9% 8.8% 40.8%
Acct.Payable 51.62
49.18
61.36
67.99
77.21
103.57
117.10
174.73
251.36
growth rate -4.7% 24.8% 10.8% 13.6% 34.1% 13.1% 49.2% 43.9%
Cur.Assets 260.91
276.17
350.83
431.73
490.85
552.53
636.23
873.95
1,455.63
growth rate 5.9% 27.0% 23.1% 13.7% 12.6% 15.2% 37.4% 66.6%
Total Assets 873.42
907.34
1,066.14
1,195.85
1,403.91
1,571.46
1,845.36
2,856.73
3,951.10
growth rate 3.9% 17.5% 12.2% 17.4% 11.9% 17.4% 54.8% 38.3%
Cash 35.61
18.54
31.83
34.76
32.55
23.98
28.17
59.76
223.63
growth rate -47.9% 71.7% 9.2% -6.3% -26.4% 17.5% 112.2% 274.2%
Inventory 94.94
109.98
146.97
171.06
185.60
252.00
329.02
471.03
782.95
growth rate 15.8% 33.6% 16.4% 8.5% 35.8% 30.6% 43.2% 66.2%
Cur.Liabilities 157.89
229.58
272.69
284.36
350.44
381.98
428.36
567.84
1,037.12
growth rate 45.4% 18.8% 4.3% 23.2% 9.0% 12.1% 32.6% 82.6%
Liabilities 391.58
368.25
418.92
432.29
524.45
526.59
656.48
1,395.73
2,217.87
growth rate -6.0% 13.8% 3.2% 21.3% 0.4% 24.7% 112.6% 58.9%
LT Debt 122.48
15.88
12.60
9.38
46.25
43.13
40.00
515.66
521.07
growth rate -87.0% -20.6% -25.6% 393.3% -6.8% -7.3% 1,189.1% 1.1%
Equity 478.34
532.45
641.44
758.01
872.03
1,036.40
1,158.72
1,438.12
1,655.87
growth rate 11.3% 20.5% 18.2% 15.0% 18.9% 11.8% 24.1% 15.1%
Common Shares 92.00
92.00
92.00
92.00
92.00
92.00
92.00
92.00
92.00
92.00
92.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 29.28
47.07
52.99
79.71
126.83
176.54
135.97
159.19
323.99
growth rate 60.8% 12.6% 50.4% 59.1% 39.2% -23.0% 17.1% 103.5%
Cash Dividends 16.88
18.41
19.97
30.73
38.71
42.40
52.54
31.34
62.68
growth rate 9.1% 8.5% 53.9% 26.0% 9.5% 23.9% -40.4% 100.0%
Cash From OA 90.11
111.31
142.79
156.66
174.69
227.29
310.13
416.88
695.97
growth rate 23.5% 28.3% 9.7% 11.5% 30.1% 36.5% 34.4% 67.0%
FCF per Share 0.44
0.03
0.34
0.81
0.88
0.71
0.79
0.62
1.22
3.24
3.86
growth rate -93.2% 1,033.3% 138.2% 8.6% -19.3% 11.3% -21.5% 96.8% 165.6% 19.1%
Sale Purchase of Stock 0.01
0.14
0.18
growth rate 1,340.0% 21.5%
FCF 22.00
10.00
61.00
64.00
90.00
77.00
48.00
51.00
174.00
258.00
696.00
growth rate -54.6% 510.0% 4.9% 40.6% -14.4% -37.7% 6.3% 241.2% 48.3% 169.8%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 588.38
683.52
884.33
1,051.61
1,081.03
1,212.15
1,440.57
1,910.08
2,886.98
growth rate 16.2% 29.4% 18.9% 2.8% 12.1% 18.8% 32.6% 51.1%
Op.Income 104.66
121.47
196.99
241.12
250.79
286.88
347.90
503.14
882.78
growth rate 16.1% 62.2% 22.4% 4.0% 14.4% 21.3% 44.6% 75.5%
IBT 94.44
105.05
169.68
212.99
220.61
284.55
317.42
460.69
646.72
growth rate 11.2% 61.5% 25.5% 3.6% 29.0% 11.6% 45.1% 40.4%
Net Income 66.28
72.44
118.00
153.68
161.09
208.05
234.50
335.93
414.41
growth rate 9.3% 62.9% 30.2% 4.8% 29.2% 12.7% 43.3% 23.4%
EPS 0.47
0.62
0.72
0.79
1.28
1.67
1.75
2.26
2.54
3.64
4.50
growth rate 31.9% 16.1% 9.7% 62.0% 30.5% 4.8% 29.1% 12.4% 43.3% 23.6%
Gross Profit 293.13
337.21
451.79
526.82
554.83
629.56
748.29
1,003.32
1,553.00
growth rate 15.0% 34.0% 16.6% 5.3% 13.5% 18.9% 34.1% 54.8%
R&D 36.00
34.12
41.53
47.54
53.21
60.62
79.22
84.45
110.49
growth rate -5.2% 21.7% 14.5% 11.9% 13.9% 30.7% 6.6% 30.8%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 197.50
216.90
229.80
238.88
261.30
growth rate 9.8% 6.0% 4.0% 9.4%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 310.50
320.30
368.30
371.72
417.10
growth rate 3.2% 15.0% 0.9% 12.2%
Acct.Payable 364.60
407.40
439.80
251.36
506.00
growth rate 11.7% 8.0% -42.9% 101.3%
Cur.Assets 1,061.80
1,252.00
1,387.80
1,455.63
1,563.30
growth rate 17.9% 10.9% 4.9% 7.4%
Total Assets 3,313.00
3,521.90
3,976.10
3,951.10
4,158.70
growth rate 6.3% 12.9% -0.6% 5.3%
Cash 149.40
254.70
226.80
223.63
165.10
growth rate 70.5% -11.0% -1.4% -26.2%
Inventory 534.80
599.60
703.90
782.95
857.50
growth rate 12.1% 17.4% 11.2% 9.5%
Cur.Liabilities 708.00
792.40
938.60
1,037.12
1,025.40
growth rate 11.9% 18.5% 10.5% -1.1%
Liabilities 1,756.80
1,828.80
2,212.70
2,217.87
2,159.10
growth rate 4.1% 21.0% 0.2% -2.7%
LT Debt 515.40
515.40
522.50
521.07
521.30
growth rate 0.0% 1.4% -0.3% 0.0%
Equity 1,530.90
1,668.50
1,668.30
1,655.87
1,923.10
growth rate 9.0% 0.0% -0.8% 16.1%
Common Shares 18.40
18.40
18.40
18.44
18.40
growth rate 0.0% 0.0% 0.2% -0.2%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 62.00
51.40
72.60
137.99
77.20
growth rate -17.1% 41.3% 90.1% -44.1%
Cash Dividends 62.70
growth rate
Cash From OA 204.00
164.10
165.50
162.37
169.20
growth rate -19.6% 0.9% -1.9% 4.2%
Sale Purchase of Stock
growth rate
FCF 142.00
112.70
92.90
24.38
92.00
growth rate -20.6% -17.6% -73.8% 277.3%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 655.20
696.70
757.00
778.18
862.50
growth rate 6.3% 8.7% 2.8% 10.8%
Op.Income 197.50
216.90
229.80
238.88
261.30
growth rate 9.8% 6.0% 4.0% 9.4%
IBT 170.90
202.80
209.50
63.72
337.80
growth rate 18.7% 3.3% -69.6% 430.1%
Net Income 114.50
144.20
147.70
8.21
270.10
growth rate 25.9% 2.4% -94.4% 3,188.7%
Gross Profit 351.80
384.30
409.90
407.30
454.50
growth rate 9.2% 6.7% -0.6% 11.6%
R&D 24.70
27.60
27.10
31.19
33.30
growth rate 11.7% -1.8% 15.1% 6.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A+ (99.58)

YOY Growth Grade:

A (85.33)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 112.34 70.49
EPS / Growth 4.31

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 17.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 17.2% 17.2% 17.2%
Future PE 0.01 17.18 17.18
Future EPS 21.02 21.02 21.02
Value Price
MOS %
0.05
-100.0%
89.24
-70.6%
89.24
-70.6%
MOS Price 0.03 44.62 44.62
IRT 15.30 15.30 15.30

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.